{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:10:42Z","timestamp":1778217042726,"version":"3.51.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Tyrosine kinase inhibitors represent the most effective and long-lasting treatment currently available for aggressive thyroid cancers, but in some patients the response is poor or absent. Recently, we demonstrated that the response to Lenvatinib is associated with alterations in\n                      <jats:italic>TP53<\/jats:italic>\n                      gene or protein. Aiming to find a novel therapeutic strategy for aggressive thyroid cancers, we investigated\n                      <jats:italic>in vitro<\/jats:italic>\n                      the DNA damage response pathway, where p53 plays a crucial role, and tested its inhibition through synthetic lethality or stress sensitization strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The DNA damage response has been characterized in a panel of p53-defective or proficient thyroid cancer cell lines both at basal level and in response to Doxorubicin, a DNA damaging agent, by western blot, immunofluorescence and MTT-based cell viability assay. We then evaluated the effect of a selective CHK1 kinase inhibitor, Prexasertib, either alone or in combination with Doxorubicin. Cell cycle variations and cell death were evaluated by flow-cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The p53-defective thyroid cancer cells showed a higher degree of genomic instability and, in response to Doxorubicin, activated not only ATM\/CHK2 but also ATR\/CHK1 to bypass p53 and induce DNA repair. We found that Prexasertib was more effective in p53-defective cells, since it significantly reduced tumor cell proliferation due to replicative failure and cell death. Moreover, Doxorubicin potentiated the Prexasertib effects in p53-defective thyroid cancer cells, yet at the lowest doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study unravels the potential of Prexasertib as a novel treatment option for aggressive thyroid cancers p53-defective and poorly responsive to tyrosine kinase inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1743111","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:35:47Z","timestamp":1778214947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandro","family":"Manzo","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa Stellaria","family":"Grassi","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Orietta","family":"Borghi","sequence":"additional","affiliation":[{"name":"Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano","place":["Milan, Italy"]},{"name":"Dipartimento di Scienze Cliniche e di Comunit\u00e0, Dipartimento di Eccellenza 2023-2027, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS","place":["Milan, Italy"]},{"name":"Department of Pathophysiology and Transplantation, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Persani","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan","place":["Milan, Italy"]},{"name":"Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cirello","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS","place":["Milan, Italy"]},{"name":"Department of Pathophysiology and Transplantation, University of Milan","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies","volume":"16","author":"Smallridge","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","article-title":"Recent advances in the management of anaplastic thyroid cancer","volume":"13","author":"De Leo","year":"2020","journal-title":"Thyroid Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090709","article-title":"Molecular alterations in thyroid cancer: from bench to clinical practice","volume":"10","author":"Tirr\u00f2","year":"2019","journal-title":"Genes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592202","article-title":"Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions","volume":"10","author":"Porter","year":"2020","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S201513","article-title":"Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.41616","article-title":"Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma","volume":"10","author":"Tang","year":"2020","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf056","article-title":"TP53 alterations associate with poor response to lenvatinib in patients with advanced thyroid cancer","volume":"1","author":"Cirello","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061325","article-title":"New insights in thyroid cancer and p53 family proteins","volume":"18","author":"Manzella","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.2000.3114","article-title":"Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations","volume":"72","author":"Shahedian","year":"2001","journal-title":"Mol Genet Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23223","article-title":"Foci formation of P53-binding protein 1 in thyroid tumors: activation of genomic instability during thyroid carcinogenesis","volume":"122","author":"Nakashima","year":"2008","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00280-019-03950-y","article-title":"Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development","volume":"85","author":"Angius","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B14","unstructured":"Data from: TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer\n          \n          \n            \n              Cirello\n              V\n            \n            \n              Colombo\n              C\n            \n            \n              Tosi\n              D\n            \n            \n              Manzo\n              A\n            \n            \n              Borghi\n              MO\n            \n            \n              Gianelli\n              U\n            \n          \n          10.5281\/zenodo.14288828\n          Zenodo\n          \n          2024"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2015.01.020","article-title":"Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells","volume":"27","author":"Vera","year":"2015","journal-title":"Cell Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00411-013-0486-5","article-title":"Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL- 60)","volume":"52","author":"V\u00e1vrov\u00e1","year":"2013","journal-title":"Radiat Environ Biophys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5799","article-title":"SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways","volume":"6","author":"Grassi","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26228","article-title":"Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells","volume":"130","author":"Messina","year":"2012","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17398","article-title":"Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164072","article-title":"Epigenetic alterations upstream and downstream of p53 signaling in colorectal carcinoma","volume":"13","author":"Tomicic","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.20517\/cdr.2020.66","article-title":"Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms","volume":"3","author":"Juhlin","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.08.019","article-title":"The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines","volume":"365","author":"Lavarone","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0001","article-title":"Efficacy of adavosertib therapy against anaplastic thyroid cancer","volume":"28","author":"Lu","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1038\/s41598-023-32092-8","article-title":"Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types","volume":"13","author":"Sasaki","year":"2023","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133200","article-title":"Poorly differentiated and anaplastic thyroid cancer: insights into genomics, microenvironment and new drugs","volume":"13","author":"Prete","year":"2021","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406879200","article-title":"Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species","volume":"279","author":"Kurz","year":"2004","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1634\/theoncologist.2020-0491","article-title":"A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild\u2010type, advanced triple\u2010negative breast cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy076","article-title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","volume":"29","author":"Italiano","year":"2018","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122068","article-title":"Non-canonical cell death induced by p53","volume":"17","author":"Ranjan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32814","article-title":"Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib","volume":"147","author":"Heidler","year":"2020","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12882","article-title":"Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation","volume":"15","author":"Zhao","year":"2021","journal-title":"Mol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1322","article-title":"CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs","volume":"18","author":"Walton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10565-021-09640-x","article-title":"Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells","volume":"39","author":"Ghelli Luserna Di Ror\u00e0","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000448621","article-title":"Phase I study of CHK1 inhibitor LY2603618 in combination with gemcitabine in patients with solid tumors","volume":"91","author":"Calvo","year":"2016","journal-title":"Oncology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1743111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:35:58Z","timestamp":1778214958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1743111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":43,"alternative-id":["10.3389\/fendo.2026.1743111"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1743111","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1743111"}}